BACKGROUND: Racial disparities in prostate cancer survival (PCS) narrowed during the prostate-specific antigen (PSA) era, suggesting that screening may induce more equitable outcomes. However, the effects of lead time and overdiagnosis can inflate survival even without real screening benefit. METHODS: A simulation model of PCS in the early PSA era (1991)(1992)(1993)(1994)(1995)(1996)(1997)(1998)(1999)(2000) was created. The modeled survival started with baseline survival in the pre-PSA era (1975)(1976)(1977)(1978)(1979)(1980)(1981)(1982)(1983)(1984)(1985)(1986)(1987)(1988)(1989)(1990) and added lead times and overdiagnosis using estimates from published studies. The authors quantified 1) discrepancies between modeled and observed PCS in the PSA era and 2) residual period effects on PCS given specified values for screening benefit. RESULTS: Lead time and overdiagnosis explained more of the improvement in PCS for older ages at diagnosis (46% [95% confidence interval (CI), 44%-50%] for blacks and 51% [95% CI, 50%-52%] for all races ages 50-54 years vs 98% [95% CI, 97%-99%] for blacks and 100% for all races ages 75-79 years). They also explained more of the narrowing in PCS disparities for older ages (33% [95% CI, 31%-43%] for men ages 50-54 years vs 74% [95% CI, 71%-81%] for men ages 75-79 years). The period effects amounted to reductions of 27% to 40% among blacks and 26% to 38% among all races in the risk of prostate cancer death, depending on the screening benefit. CONCLUSIONS: Real improvements in survival disparities in the PSA era are smaller than those observed and reflect similar reductions in the risk of prostate cancer death among blacks and all races. Understanding screening artifacts is necessary for valid interpretation of observed survival trends. Cancer 2018;124:1752-9.
INTRODUCTION
There are substantial racial disparities in prostate cancer in the United States, and black men have mortality rates approximately double those of white men. 1 Since the widespread adoption of prostate-specific antigen (PSA) screening for prostate cancer in the early 1990s, there has been a clear narrowing of the disparities in mortality (Fig. 1 ). Powell and colleagues 2 noted this trend and offered it as evidence in favor of early and aggressive screening among black men. However, it is well known that screening induces artifactual effects, which can inflate observed survival even in the absence of any screening benefit. Therefore, the objective of this study was to determine the extent to which changes in survival disparities during the PSA era reflect real survival improvement beyond artifacts of screening.
The term artifacts of screening refers to the predictable effects of screening on survival that are known to occur even in the absence of benefit. These include lead time, defined as the time by which screening advances diagnosis, and overdiagnosis, which is the detection of cases that would not have been diagnosed within the patient's lifetime in the absence of screening. Retrospective studies of screening uptake in the United States have demonstrated the rapid and widespread adoption of screening among both blacks and all races. 3 Real survival improvement refers to the true reduction in prostate cancer mortality after excluding artifacts of screening and may be attributed to true benefit of screening or other changes in disease management in preventing or delaying prostate cancer mortality.
For this study, first, we determined the portion of the improvement in disease-specific survival that could be explained by lead time and overdiagnosis, which we previously estimated separately for blacks and all races. 4, 5 Then, we analyzed the unexplained portion of the observed improvement to make inferences about patterns of real survival improvement among blacks and all races during the PSA era.
MATERIALS AND METHODS

Overview
Use of the PSA test for prostate cancer screening in the United States began in the late 1980s and increased rapidly after 1990. 3 We consider the years before and including 1990 as the pre-PSA era and the years from 1991 onward as the post-PSA or PSA era. Our analysis uses 3 types of net (in the absence of death from other causes) survival curves. The observed pre-PSA curve is the survival among patients in the Surveillance, Epidemiology, and End Results (SEER) database who were diagnosed with prostate cancer in calendar years 1975 through 1990, and the observed post-PSA curve is the survival among patients in the SEER database who were diagnosed with prostate cancer calendar years 1991 through 2000. The modeled post-PSA curve is a projection of PSA-era survival that results from adding the artifacts of screening to the observed pre-PSA curve. By comparing the modeled curve against the pre-PSA and post-PSA curves, we calculate the proportion of change in 10-year survival from the pre-PSA era to the post-PSA era that is solely because of artifact. When this proportion is less than 1, we analyze implications for real survival improvements.
Data
We use SEER*Stat 6 to calculate 10-year net diseasespecific survival for men who were diagnosed with prostate cancer in the core 9 registries by race group (blacks and all races), 5-year age group (from ages 50-54 to 75-79 years at diagnosis), and diagnosis in the pre-PSA and post-PSA years.
We source estimates of lead time, fractions of cases detected by screening, and fractions of overdiagnosed cases from the Fred Hutchinson Cancer Research Center (Fred Hutch) model of prostate cancer in the US population. 7, 8 The model produces individual-level disease histories with and without screening for blacks and all races, 4, 5 which can be used to produce the requisite inputs for deriving the modeled curves.
Deriving Modeled Post-PSA Curves
In the pre-PSA era, all cases were clinically diagnosed (ie, they were diagnosed without screening). In contrast, the post-PSA curve represents a combination of screendetected and nonscreen-detected cases. The patients with screen-detected disease comprise a combination of overdiagnosed and nonoverdiagnosed cases. Overdiagnosed patients cannot die of disease; their disease-specific survival is 100% by definition. It is impossible to know whether an individual patient has been overdiagnosed, although associations with patient and tumor features have been identified. 9, 10 Nonoverdiagnosed patients have a survival time that is the sum of the lead time and a postlead-time survival time that begins when they would have been diagnosed without screening. If baseline survival does not change over time, then the modeled post-PSA survival time is as follows:
T PSA 5ð12PÞ T PRE 1 P½ð12QÞðT PRE 1LÞ1Q; (1) where T PRE is the observed pre-PSA era survival time, P is the fraction of cases that are screen detected, Q is the fraction of screen-detected cases that are overdiagnosed during the PSA era, and L is the lead time. The first term on the right-hand side of Equation (1) represents the nonscreen-detected fraction, and the second term represents the screen-detected fraction.
We simulate times T PSA by generating times T PRE based on SEER data and estimates of P, Q, and L from the Fred Hutch model. We present 2 types of estimates. The first uses only the estimated mean lead times from this model and samples from exponential distributions to simulate values for L. The second samples from the full distribution of lead times output by the Fred Hutch model. Details of this process are provided in Section 1 of the Supporting Methods (Simulation Modeling to Project Effects of Lead Time and Overdiagnosis; see online supporting information). Sample sizes are set to observed numbers of men in each race and age group at diagnosis in the pre-PSA era, and 95% confidence intervals indicate the associated uncertainty in estimated survival. QUANTIFYING SURVIVAL IMPROVEMENT AND SURVIVAL DISPARITY EXPLAINED BY ARTIFACT For each race and age group at diagnosis, the proportion q of the survival improvement in the PSA era explained by artifacts of screening is:
where A is the observed 10-year survival in the pre-PSA era, B is the modeled 10-year survival in the PSA era, and C is the observed 10-year survival in the PSA era. In general, B will lie between A and C. The proportion q reflects the improvement explained by artifacts of screening as a fraction of the entire survival improvement between eras. If B is close to C, then most of the survival improvement is explained by artifact, and the proportion explained is close to 1; however, if B is close to A, then the proportion explained is close to 0. In addition, for each age group at diagnosis, the proportion q 0 of the improvement in the survival disparity in the PSA era explained by artifacts of screening is given by the same ratio except that A is the difference in observed 10-year survival between blacks and all races in the pre-PSA era, B is the difference in modeled 10-year survival between blacks and all races in the PSA era, and C is the difference in observed 10-year survival between blacks and all races in the PSA era.
Sensitivity Analysis
It is clear that q and q 0 may be sensitive to the input values for lead times and frequencies of cases detected by screening and overdiagnosed cases. To investigate this sensitivity, we recalculate q and q 0 varying these inputs over a range consistent with that used in a prior study. 11 Specifically, we simultaneously increase or decrease mean lead times and overdiagnosis frequencies within each age group by 20%, generate the resulting modeled 10-year survival (or difference in 10-year survival between blacks and all races) in the PSA era, then recalculate q and q 0 .
Inferring Real Survival Improvement for All Cases and for Cases Detected by Screening
When the estimated value of q is less than 1, we conclude there is a real survival improvement in the PSA era compared with the pre-PSA era. We partition the real survival improvement into a period effect that applies to all prostate cancer cases and an effect associated with screen detection. Specifically, the period effect d is a relative risk that acts on both instances of T PRE in Equation (1), whereas the screen-detection effect l is a relative risk that acts only on the second instance of T PRE (ie, on screen-detected cases). We estimate d given a range of fixed values for l that includes estimates of PSA screening benefit from published trials. A lower limit of 0.5 is motivated by the Goteborg Randomized Prostate Cancer Screening Trial, 12, 13 and an upper limit of 1.0 is motivated by the Prostate, Lung, Colorectal, and Ovarian cancer screening trial. 14, 15 Details and outputs of the estimation procedure can be found in Section 2 of the Supporting Methods (Inferring Survival Improvement; see online supporting information). Figure 2 illustrates 10-year disease-specific survival and 95% confidence intervals 16 for prostate cancer cases detected in SEER by race group. Observed diseasespecific survival curves are illustrated in Figure 3 separately for the pre-PSA and PSA eras. Figures 2 and 3 illustrate the narrowing of survival differences between blacks and all races diagnosed with prostate cancer after the introduction of PSA screening. Table 1 provides the fraction of cases detected by screening in the post-PSA era, the fraction of screendetected cases that were overdiagnosed, and the mean lead times produced by the Fred Hutch model for blacks and all races. The full lead-time distributions produced by the Fred Hutch model are illustrated in Supporting Figure 1 (see online supporting information). The screen-detected fraction is similar across age groups and is generally slightly lower for blacks than for all races. The fraction overdiagnosed ranges from approximately 10% for men diagnosed at ages 50 to 54 years to almost 60% for men diagnosed at ages 75 to 79 years. The mean lead time among nonoverdiagnosed cases decreases with age because these patients must have a date of diagnosis without screening that precedes their date of other-cause death. Both overdiagnosis frequencies and mean lead times are similar for blacks and for all races. This is consistent with 2 other models of prostate cancer natural history previously calibrated to SEER incidence data. 4, 5 Figure 4 illustrates observed pre-PSA, modeled post-PSA, and observed post-PSA survival curves by race and age group. We observe that artifacts of screening explain most of the observed survival improvement for older men; modeled post-PSA curves approach observed post-PSA curves. However, artifacts of screening explain much less of the observed survival improvement for younger men. Table 2 lists the proportion of the improvement in 10-year survival explained by artifacts of screening, and Table 3 lists the proportion of the improvement in 10-year survival disparity explained by artifacts of screening. Screening artifacts explain less of the survival improvement and less of the change in survival disparity among younger men than among older men. A similar pattern is Figure 3 . Observed disease-specific survival curves are illustrated by age group at diagnosis (columns) and by years since diagnosis in (Top) the era before prostate-specific antigen (PSA) testing and (Bottom) during the PSA era. observed under 1-way sensitivity analysis (Supporting Table 1 ; see online supporting information). In all settings, the proportion explained by artifacts remains considerably lower for younger men. Relaxing the exponential assumption and using the full range of lead times from the Fred Hutch model rather than only the mean value produces similar results, as indicated in Section 3 of the Supporting Methods (Results Relaxing Exponential Assumptions; see online supporting information). Tables 2 and 3 also indicate that there are real survival improvements beyond those explained by artifacts of screening. Table 4 presents the best-fitting values for the period effect (d) across the values for the assumed effect of screen detection (l) for men ages 50 to 79 years; results for individual age groups are provided in Supporting Table 4 (see online supporting information). The magnitude of the period effect depends on the specified effect associated with screen detection. If it is believed, for example, that screen detection is not efficacious, then the period effect amounts to a 38% (all races) to 40% (blacks) reduction in the risk of prostate cancer death. However, if screen detection is as efficacious as suggested by the European Randomized Study of Screening for Prostate Cancer (21% reduction in mortality risk 17 ) , then the period effect amounts to a 34% (all races) to 35% (blacks) reduction in the risk of prostate cancer death. In general, provided the effect of screen detection is similar among blacks and all races, the period effect is also similar. Supporting Table 4 indicates that this finding persists within individual age groups (see online supporting information). The estimated period effect is largest among younger men and is slightly stronger for black men than for men of all races for most assumed values for the screen-detection effect.
RESULTS
DISCUSSION
Since the advent of PSA screening, the profile of prostate cancer in the United States has changed dramatically. Reductions in disease-specific mortality have been accompanied by a narrowing of racial disparities in diseasespecific survival, leading to some optimism about the ability of screening to reduce established inequities in the burden of the disease. 2 The current study explores the extent to which these apparent trends in disparities are real. We observe that a sizeable portion of these trends, in fact, are not real; rather, they are attributable to artifacts of screening, particularly in older men. Indeed, among the oldest men in our analysis, artifacts of screening explain 69% of the narrowing in 10-year survival disparities. For younger men, artifacts of screening explain only 35% of the narrowing in 10-year survival disparities.
Our results indicate that, overall, there has been a real and clinically significant improvement in survival during the PSA era among men with prostate cancer, Figure 4 . Observed survival in the era before prostate-specific antigen (PSA) testing, modeled survival incorporating artifacts of screening, and observed post-PSA survival are illustrated according to (columns) age group at diagnosis (Top) for all races and (Bottom) for blacks.
including nonscreen-detected cases. Indeed, we can identify a period effect reflecting real survival improvement across a range of plausible effects of early detection. The period effect amounts to a reduction in the risk of diseasespecific death that ranges from 27% to 40% for blacks and from 26% to 38% for all races. This period effect is likely attributable to a series of factors, including treatment availability, advances in cancer therapy (in both the primary and salvage settings), and earlier identification of disease recurrence after diagnosis. Data on treatment trends indicate widespread adoption of primary prostate surgery in the late 1980s and early 1990s 18 and increased use of adjuvant hormone blockade with primary radiation for patients with high-risk, localized disease in the 1990s. 19 Both of these treatments have been associated with significant benefit in randomized trials. 20, 21 Furthermore, the use of PSA monitoring after primary therapy has led to earlier detection and treatment of recurrence, which has been associated with significant benefit.
22,23
Limitations
Our approach relies on prostate cancer incidence and survival data from the SEER database. Although concerns about representativeness have been raised, 24 this database is widely recognized as a high-quality source of information about national cancer trends. Furthermore, our analysis incorporates estimates of the frequency of screendetected cases, the frequency of overdiagnosed cases, and the lead time among those not overdiagnosed based on a model of prostate cancer natural history in the United States. Inaccuracies in these estimates could translate into biases in our results; however, sensitivity analysis indicates that our conclusions are quite robust.
Our approach also makes several simplifying assumptions. First, in the absence of screening benefit, we assume that the distribution of disease-specific survival after clinical diagnosis is the same for cases not screen detected and for (nonoverdiagnosed) cases detected by screening. Furthermore, we assume that both survival distributions are well approximated by the observed, pre-PSA survival. When we estimate the real survival improvement during the PSA era, we assume that the period effect and the effect of early detection are independent.
An additional limitation is that, when we report confidence intervals for the proportion of the improvement and change in disparity attributable to artifacts of screening, we do not account for uncertainty in inputs from the Fred Hutch model (ie, the fraction of men diagnosed by screening, the fraction overdiagnosed, or the mean lead times). Finally, our primary results are based on 10-year survival rather than on the entire survival curve. Results may be mildly sensitive to the specific point selected, but we have observed that choosing a different point, such as 5-year survival (Supporting Table 2 ; see online supporting information), does not materially affect our conclusions. We do not anticipate that our primary conclusions will change with longer follow-up.
In conclusion, we do not dispute that long-standing racial disparities in prostate cancer survival may be narrowing. However, the real survival improvement during the PSA era is more modest than that observed. Understanding the age-specific and race-specific patterns of screening artifacts on disease-specific survival trends is a necessary prerequisite if we are to use these trends to develop prostate cancer screening policies that are appropriate for black men and for the general population. 
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